

<b>NDA</b>	208255
<b>Submission Type</b>	505(b)(2)
<b>Submission Date</b>	09/13/2016
<b>Generic Name</b>	Efavirenz (EFV), Lamivudine (3TC), Tenofovir DF (TDF)
<b>Brand Name</b>	N/A
<b>Indication</b>	Treatment of HIV
<b>Dosage Form/ Strength</b>	Tablet: EFV (400 mg) / 3TC (300 mg) / TDF(300 mg)
<b>Applicant</b>	Mylan
<b>Review Team</b>	Islam R. Younis, Ph.D.

## Background

This 505(b)(2) application was submitted under the provisions of the President's Emergency Plan for AIDS Relief (PEPFAR). The applicant developed a fixed dose combination (FDC) tablet containing EFV, 3TC, and TDF. This is the first application to seek approval for an HIV regimen containing 400 mg EFV. The currently approved EFV therapeutic dose is 600 mg.

## Basis for Approval

The applicant obtained right of reference to ENCORE1 clinical trial which established the efficacy and safety of the 400 mg dose of EFV. ENCORE1 was randomized, double-blind, active-controlled, two-arm, parallel groups multinational clinical trial which evaluated the safety and efficacy of EVF 400 mg dose relative to EVF 600 mg dose. In both treatment arms EFV was administered once daily in combination with Truvada<sup>®</sup>, a FDC of emtricitabine (FTC, 200 mg) and TDF (300 mg). The proportion of patients with a viral load < 200 copies/mL in the mITT analysis was 302/321 (94.08%) in the EFV 400 mg treatment arm and 285/309 (92.23%) in the EFV 600 mg treatment arm (difference 1.85, 95% CI -2.1 to 5.79).

The applicant conducted a relative bioavailability study (Study C15275) to compare the exposures of EFV, 3TC, and TDF following the administration of the FDC tablet and the individual EFV (Efamat 200 mg), 3TC (Epivir<sup>®</sup> 300 mg), and TDF (Viread<sup>®</sup> 300 mg) agents administered in combination. This study bridges efficacy and safety information from ENCORE1 to the FDC tablet because Efamat is the EFV formulation used in ENCORE1. The exposure of EFV, 3TC, and TDF were similar following the administration of the FDC relative to the individual agents (Table 1).

Drug	Parameter	Geometric Mean Ratio (90% CI)
Efavirenz	AUC <sub>0-72</sub>	0.96 (0.92,1.0)
	Cmax	0.92(0.85,0.99)
Lamivudine	AUC	1.04 (0.99,1.08)
	Cmax	0.89(0.83,0.96)
Tenofovir	AUC	1.03(0.98,1.07)
	Cmax	0.96(0.90,1.02)

## Recommendations

The application is recommended for approval from clinical pharmacology perspective. The indication can be extended to pediatrics 12 years of age and older and weighing at least 35 Kg. The pharmacokinetics of EFV is linear in the dose range 200 to 600 mg; therefore the administration of EFV 400 mg dose is expected to produce exposure in adolescents similar to those observed in adults in similar manner to what was observed with EFV 600 mg dose. The efficacy of the 400 mg dose of EFV was shown to be non-

inferior to EFV 600 mg dose in adults. Safety of EFV 600 mg dose in adolescents has been established and therefore there is no need to obtain additional safety information for EFV 400 mg dose in adolescents.

**Labeling Recommendations**

Labeling negotiations were ongoing at the time of this review.

Relative Bioavailability Study			
<b>Study #</b>	C15275	<b>Study Period</b>	11/20/2015-12/23/2015
<b>Title</b>	A randomized, open-label, balanced, two-treatment, two-period, two-sequence, single-dose, crossover oral bioequivalence study of Test product Tenofovir disoproxil fumarate, Lamivudine and Efavirenz film-coated tablets 300 mg / 300 mg/ 400 mg of Mylan Laboratories Limited, India with Reference product (R= R1 + R2 + R3) (R1: VIREAD® Tablets (Tenofovir disoproxil fumarate) 300 mg manufactured and distributed by Gilead Sciences, Inc. Foster City, CA 94404, R2: EPIVIR® Tablets (Lamivudine) 300 mg Manufactured by GlaxoSmithKline Research Triangle Park, NC 27709, R3: Two tablets of Efamat (Efavirenz) 200 mg manufactured by Mylan Laboratories Ltd, India), in normal healthy adult human subjects under fasting conditions.		
<b>STUDY DESIGN</b>			
Randomized, open-label, balanced, two-treatment, two-period, two-sequence, single-dose, crossover study. Washout period was 24 days.			
Population	<input checked="" type="checkbox"/> Healthy Volunteers <input type="checkbox"/> Patients		
Study Rationale	To evaluate the relative bioavailability of EFV, 3TC, and TDF following the administration of film-coated fixed dose combination (Mylan FDC) relative to the individual agents administered in combination		
Treatments	Arm	API( Trade Name)	Batch No., Expiry date
	Test	EFV, 3TC, TDF (FDC Tablet)	2009057/ April 2017
	Reference	TDF 300 mg(Viread®)	002181/July 2018
		3TC 300 mg (EpiVir®)	3ZP8520/July 2016
		EFV 200 mg (Efamat): 2 tablets	8036093/March 2018
Dose Selection Rationale	EFV dose is the dose evaluated in ENCORE1 clinical efficacy and safety trial. 3TC and TDF doses are the approved therapeutic doses and the reference listed formulation was used in the study		
Administration	<input checked="" type="checkbox"/> Fasted <input type="checkbox"/> Fed		
Interfering Substances Excluded	Caffeine and xanthine-containing foods or beverages (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas,etc.), any Grapefruit juice or related products, tobacco containing products.		
Sampling Times	Pre-dose, 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.25, 1.50, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.		
PK Parameters	Primary: AUC <sub>t</sub> (AUC <sub>0-72</sub> for EFV), C <sub>max</sub> Secondary: T <sub>max</sub> , t <sub>1/2</sub> , K <sub>el</sub> (All) AUC <sub>0-inf</sub> and AUC <sub>0-t</sub> / AUC <sub>0-inf</sub> *100 (		
PK Analysis	Non-compartment analysis using linear trapezoidal method		
Statistical Analysis	ANOVA including sequence, formulation and period as fixed effects and subject (sequence) as a random effect. Sequence effect was tested using subject (sequence) as an error term.		
Is the study design acceptable? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			
<b>STUDY CONDUCT</b>			
<b>Bioanalytical Method:</b>			
Analyte	EFV	3TC	Tenfovir
Method Type	LC/MS-MS	LC/MS-MS	LC/MS-MS
Range	100-4000 ng/mL(revised LLOQ to 50 ng/mL)	5 – 600 ng/mL	24 – 400 ng/mL
Matrix	Plasma	Plasma	Plasma
Validation	▪ Method validated prior to use		<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA

	▪ Method validation acceptable	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA
Study Samples Analysis	▪ Samples analyzed within the established stability period	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	▪ Quality control samples range acceptable	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	▪ Chromatograms provided	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	▪ Accuracy and precision of the calibration curve acceptable	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	▪ Accuracy and precision of the quality control samples acceptable	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	▪ Incurred samples analysis is acceptable	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	▪ Overall performance acceptable	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Inspection	▪ Will the bioanalytical site be inspected	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

**Protocol Deviations**

- Are there any protocol deviations listed in the study report?  Yes  No
- Do any of the listed deviations affect the integrity of the study?  Yes  No  NA

**Notes:**

*For some subjects, plasma samples in period I and Period II were collected beyond the scheduled sampling time. There was no impact on the study outcome as actual time points of sample collection was used for pharmacokinetic analysis.*

**STUDY RESULTS****Study Population**

Enrolled	76
Treated	70
Completed	64
Discontinued Due to AE	1
PK Population/Safety Population	64 (62 for EFV)/65
Age [Mean (SD)]	32 (5.8)
Male/Female	Not Available
Race (Caucasian/Black/Asian/Hispanic)	Indian Asian (All)

**Pharmacokinetics (Geometric Mean Ratio & 90% CI)**

Drug	Parameter	GMR (90% CI)
Efavirenz	AUC <sub>0-72</sub>	0.96 (0.92,1.0)
	C <sub>max</sub>	0.91 0.85,0.99)
Lamivudine	AUC	1.04 (0.99,1.08)
	C <sub>max</sub>	0.89 0.83,0.96)
Tenofovir	AUC	1.03 0.98,1.07)
	C <sub>max</sub>	0.96 0.90,1.02)

- Were there any outliers or excluded data from analysis?  Yes  No  NA

*Subjects 27 and 71 were excluded from pharmacokinetic and statistical data analysis of EFV as these subjects have predose concentrations of EFV for both periods greater than 5% of C<sub>max</sub>. The exclusion of these subjects does not affect trial outcome because the trial had sufficient power (post hoc estimate of ~ 100%) to evaluate similarity in exposure. Including these subjects in the analysis did not change study outcomes.*

- Are the study results acceptable?  Yes  No

**Safety**

Was there any death or serious adverse events?  Yes  No

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

ISLAM R YOUNIS  
02/17/2017